...
首页> 外文期刊>Journal of Cancer Research and Therapeutics >Evaluation of circulating miR-21 and miR-222 as diagnostic biomarkers for gastric cancer
【24h】

Evaluation of circulating miR-21 and miR-222 as diagnostic biomarkers for gastric cancer

机译:评价循环miR-​​21和miR-222作为胃癌的诊断生物标志物

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Introduction: Gastric cancer is responsible for a large number of death worldwide and its high death rate is associated with a lack of noninvasive tools in GC diagnosis. MicroRNAs (miRNAs), as gene regulators, were shown to dysregulate in different types of cancer. Moreover, it is proven that miRNAs are stable in serum/plasma, so they can be used as a potential noninvasive marker in GC diagnosis. The objective of this study is to investigate the plasma miRNA expression in GC samples compared to controls as a potential biomarker in cancer diagnosis. Materials and Methods: Expression levels of miR-21 and miR-222 were assessed using quantitative real-time polymerase chain reaction in plasma of 30 GC patients and 30 healthy controls. Diagnostic value of selected miRNAs was evaluated using receiver operating characteristic curve. Target prediction was done using bioinformatics tools to investigate the signaling pathways and function of the selected miRNAs. Results: Our results demonstrated that the expression levels of miR-21 and miR-222 were significantly higher in GC plasma than in the controls (P 0.0001, P = 0.043). The sensitivity and specificity for miR-21 and in plasma were 86.7% and 72.2% and for miR-222 were 62.5% and 56.2%, respectively. Bioinformatics analysis revealed that most target genes of miR-21 and miR-222 are involved in cancer-related signaling pathway such as tumor initiation and progression. Conclusion: Our results indicated that miR-21 and miR-222 in plasma samples can be served as a potential noninvasive tool in GC detection. Furthermore, the miRNA target prediction manifested that miR-21 and miR-222 involve in key processes associated with GC initiation and development.
机译:简介:胃癌是导致全球大量死亡的原因,其高死亡率与GC诊断中缺乏非侵入性工具有关。 MicroRNA(miRNA)作为基因调节剂,在不同类型的癌症中显示出失调。此外,已证明miRNA在血清/血浆中稳定,因此它们可用作GC诊断中潜在的非侵入性标记。这项研究的目的是研究与对照相比,GC样品中血浆miRNA的表达,作为癌症诊断中潜在的生物标记物。材料和方法:使用定量实时聚合酶链反应评估30例GC患者和30例健康对照者血浆中miR-21和miR-222的表达水平。使用受体工作特征曲线评估所选miRNA的诊断价值。使用生物信息学工具完成目标预测,以研究所选miRNA的信号传导途径和功能。结果:我们的结果表明,GC血浆中miR-21和miR-222的表达水平明显高于对照组(P <0.0001,P = 0.043)。对miR-21和血浆的敏感性和特异性分别为86.7%和72.2%,对miR-222的敏感性和特异性分别为62.5%和56.2%。生物信息学分析表明,miR-21和miR-222的大多数靶基因都参与了与癌症相关的信号通路,例如肿瘤的发生和发展。结论:我们的结果表明血浆样品中的miR-21和miR-222可作为GC检测中潜在的无创工具。此外,miRNA靶标预测表明miR-21和miR-222参与了与GC起始和发育相关的关键过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号